Prakhar Agrawal
Stock Analyst at Cantor Fitzgerald
(2.76)
# 1,867
Out of 4,902 analysts
55
Total ratings
36.73%
Success rate
0.8%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Prakhar Agrawal
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| GPCR Structure Therapeutics | Reiterates: Overweight | $65 | $19.60 | +231.63% | 13 | Jun 23, 2025 | |
| ORIC ORIC Pharmaceuticals | Reiterates: Overweight | n/a | $11.18 | - | 7 | May 6, 2025 | |
| TVTX Travere Therapeutics | Reiterates: Overweight | n/a | $16.66 | - | 3 | Apr 23, 2025 | |
| ACRS Aclaris Therapeutics | Reiterates: Overweight | n/a | $1.58 | - | 1 | Mar 18, 2025 | |
| MTSR Metsera | Initiates: Overweight | n/a | $43.73 | - | 1 | Feb 25, 2025 | |
| KROS Keros Therapeutics | Downgrades: Neutral | n/a | $14.49 | - | 3 | Jan 21, 2025 | |
| ATYR aTyr Pharma | Initiates: Overweight | n/a | $5.84 | - | 1 | Jan 6, 2025 | |
| TLSI TriSalus Life Sciences | Initiates: Overweight | $10 | $4.71 | +112.31% | 1 | Dec 17, 2024 | |
| MDGL Madrigal Pharmaceuticals | Reiterates: Neutral | n/a | $344.97 | - | 4 | Nov 20, 2024 | |
| MLTX MoonLake Immunotherapeutics | Reiterates: Overweight | n/a | $52.52 | - | 10 | Sep 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $53.60 | - | 5 | Jun 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $10.52 | - | 2 | Feb 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $24 | $38.84 | -38.21% | 2 | Apr 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $450 | $3.25 | +13,746.15% | 1 | Jul 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $14 | $0.41 | +3,274.31% | 1 | Mar 3, 2021 |
Structure Therapeutics
Jun 23, 2025
Reiterates: Overweight
Price Target: $65
Current: $19.60
Upside: +231.63%
ORIC Pharmaceuticals
May 6, 2025
Reiterates: Overweight
Price Target: n/a
Current: $11.18
Upside: -
Travere Therapeutics
Apr 23, 2025
Reiterates: Overweight
Price Target: n/a
Current: $16.66
Upside: -
Aclaris Therapeutics
Mar 18, 2025
Reiterates: Overweight
Price Target: n/a
Current: $1.58
Upside: -
Metsera
Feb 25, 2025
Initiates: Overweight
Price Target: n/a
Current: $43.73
Upside: -
Keros Therapeutics
Jan 21, 2025
Downgrades: Neutral
Price Target: n/a
Current: $14.49
Upside: -
aTyr Pharma
Jan 6, 2025
Initiates: Overweight
Price Target: n/a
Current: $5.84
Upside: -
TriSalus Life Sciences
Dec 17, 2024
Initiates: Overweight
Price Target: $10
Current: $4.71
Upside: +112.31%
Madrigal Pharmaceuticals
Nov 20, 2024
Reiterates: Neutral
Price Target: n/a
Current: $344.97
Upside: -
MoonLake Immunotherapeutics
Sep 23, 2024
Reiterates: Overweight
Price Target: n/a
Current: $52.52
Upside: -
Jun 20, 2024
Reiterates: Overweight
Price Target: n/a
Current: $53.60
Upside: -
Feb 20, 2024
Downgrades: Neutral
Price Target: n/a
Current: $10.52
Upside: -
Apr 17, 2023
Reiterates: Overweight
Price Target: $24
Current: $38.84
Upside: -38.21%
Jul 15, 2022
Assumes: Overweight
Price Target: $450
Current: $3.25
Upside: +13,746.15%
Mar 3, 2021
Initiates: Buy
Price Target: $14
Current: $0.41
Upside: +3,274.31%